Mark Scott, chief executive of (), spoke to Proactive London's Andrew Scott following the release of their pre-close trading statement for 2018.
Strong like-for-like growth at its big pharma consultancy division, known as health, offset a slower outcome from brand and marketing operation Signal.
The health division also saw good like-for-like gross profit growth and better-operating margins.
Meet Clinigen Group PLC, MaxCyte, Cello Health PLC, Oncimmune and Silence Therapeutics PLC at our event,
London , 11 July 2019.
Register here »